Publications

REPRESENTATIVE WORK

1. “Physician Agency and Adoption of Generic Pharmaceuticals” American Economic Review, 2012, 102(6): 2826–2858.  

2. “Experts’ Agency Problems: Evidence from the Prescription Drug Market in Japan,”    RAND Journal of Economics, 2007, 38(3): 844–862. 

3. “Is Zero a Special Price? Evidence from Child Healthcare” (with H. Shigeoka). American Economic Journal: Applied Economics. 2022. 14(4):381-410. NBER.  SSRN.  

4. "The Effect of Prescription Drug Advertising on Doctor Visits,”   (with Ginger Zhe Jin)  Journal of Economics and Management Strategy, 2005, 14(3): 701-727.

5. "Association of the National Health Guidance Intervention for Obesity and Cardiovascular Risks With Health Outcomes Among Japanese Men" (with S. Fukuma, T. Ikenoue, Y. Tsugawa) JAMA Intern Med. 2020. 180(12): 1630-1637.    

6. "False Alarm? Estimating the Marginal Value of Health Signals" (with K. Nishiyama, B.K. Chen, K Eggleston). Journal of Public Economics. Mar. 2021. Vol. 195. 

PUBLISHED PAPERS

1. “Asymmetric Demand Response when Prices Increase and Decrease: The Case of Child Healthcare” (with H. Shigeoka). Review of Economics and Statistics. 2023. 105 (5): 1325–1333. NBER. SSRN.

2. "Effect of age-based left-digit bias on stroke diagnosis: Regression discontinuity design," (with S. Fukuma, R. Ikesu, Y. Tsugawa). Social Science & Medicine, Vol. 334, 2023. 116193.

3. “Is Zero a Special Price? Evidence from Child Healthcare” (with H. Shigeoka). American Economic Journal: Applied Economics. 2022. 14(4):381-410. NBER.  SSRN.  

4. "Impact of the national health guidance intervention for obesity and cardiovascular risks on healthcare utilisation and healthcare spending in working-age Japanese cohort: regression discontinuity design" (with S. Fukuma, M. Mukaigawara, Y. Tsugawa). BMJ Open. 2022. 12(7): e056996. 

5. "False Alarm? Estimating the Marginal Value of Health Signals" (with K. Nishiyama, B.K. Chen, K Eggleston). Journal of Public Economics. Mar. 2021. Vol. 195. 論文の解説 (This paper is a substantially revised version of the previously-circulated paper entitled “Is Preventive Care Worth the Cost? Evidence from Mandatory Checkups in Japan.” )

6. "Association of the National Health Guidance Intervention for Obesity and Cardiovascular Risks With Health Outcomes Among Japanese Men" (with S. Fukuma, T. Ikenoue, Y. Tsugawa) JAMA Intern Med. 2020. 180(12): 1630-1637.  論文の解説

7.  "Are quality-adjusted medical prices declining for chronic disease? Evidence from diabetes care in four health systems", (with K. Eggleston, B. Chen, et al.)   European Journal of Health Economics, 2020. 

8. "Promoting Innovation in Small Markets: Evidence from the Market for Rare and Intractable Diseases", (with G. Uchida)  Journal of Health Economics, 2017. 54: 56-65. WP   論文の概要

9. "Avoidable Hospital Admissions From Diabetes Complications In Japan, Singapore, Hong Kong, And Communities Outside Beijing", (with J. Quan et al.)  Health Affairs, 2017. 36(11): 1896-1903. 

10. "Patient Cost Sharing and Medical Expenditures for the Elderly," (with K. Fukushima, S. Mizuoka, and S. Yamamoto Journal of Health Economics, 2016. 45: 115–130.   WP    論文の概要

11. "The Impact of Physician Supply on the Healthcare System: Evidence from Japan’s New Residency Program," (with Y. Watanabe)   Health Economics, 2016, 25(11): 1433–1447. WP    論文の概要

12. "Cartel sustainability in retail markets: Evidence from a health service sector" (with U. Goto),   International Journal of Industrial Organization, 2016, 49:36–58. 

13. "Markets with Physician Dispensing,"   Encyclopedia of Health Economics, 2014, Vol. 2, p. 221-227. Tony Culyer ed. Elsevier

14. “Durable Goods Price Cycles: Evidence from the Textbook Market,” (with R. Bond)  Economic Inquiry, 2014, 52(2): 518-538.  WP

15. "Does Higher Malpractice Pressure Deter Medical Errors?"   Journal of Law and Economics, 2013, 56(1): 161-188. WP 

16. “Physician Agency and Adoption of Generic Pharmaceuticals” American Economic Review, 2012, 102(6): 2826–2858.    WP

17. "The Japanese Generic Drug Market: Will it Finally Take-off?" (with K. Kubo),  Health Economics, Policy and Law, 2011, 6(3): 369-389

18. "Generic Entry in a Regulated Pharmaceutical Market,"   Japanese Economic Review, 2009, 60(1): 63-81.    WP  論文の概要 

19. "The Economics of Pharmaceutical Pricing and Physician Prescribing in Japan,"   in Prescribing Cultures and Pharmaceutical Policy in the Asia Pacific. K. Eggleston, ed., Brooking Press, 2009.   WP

20.  “Experts’ Agency Problems: Evidence from the Prescription Drug Market in Japan,”    RAND Journal of Economics, 2007, 38(3): 844–862.     WP

21. “Direct to Consumer Advertising and Prescription Choice.” (with Ginger Zhe Jin),  Journal of Industrial Economics, 2007, 55(4): 771-771.     WP

22. “An Empirical Analysis of Planned Obsolescence,” Journal of Economics and Management Strategy, 2007, 16(1): 191-226.     WP  

23. "The Effect of Prescription Drug Advertising on Doctor Visits,”   (with Ginger Zhe Jin)  Journal of Economics and Management Strategy, 2005, 14(3): 701-727.     WP 

24. ”What Explains the Use of Direct to Consumer Advertising of Prescription Drugs?”  Journal of Industrial Economics, 2004, 52(3): 349-379.     WP

WORKING PAPERS

• "Robots and Labor in the Service Sector: Evidence from Nursing Homes." (with Karen Eggleston and Yong Suk Lee). 2021. NBER. SSRN.

• "Free for Children? Patient Cost-sharing and Healthcare Utilization,” (with H. Shigeoka) 2018  SSRN, NBER

  • 子供医療費助成が医療費と健康に及ぼす影響を分析

• "Pay-for-Performance and Selective Referral in Long-Term-Care,” (with H. Noguchi and S. Sugawara), 2017  

  • 介護における成果報酬の効果を分析

• "Is Preventive Care Worth the Cost? Evidence from Health Checkups in Japan,” (with K. Nishiyama, B. Chen, K. Eggleston), 2017 

  • 健診を契機とした予防医療の費用対効果を分析

    • CATO Institute Research Briefs in Economic Policy No. 87, 2017 

    • NBER Bulletin on Aging and Health 2017, No. 3 p.4-5